The Effect of Postoperative Therapy on the Quality of Life of Patients With Early Cervical Cancer Research

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

180 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the women's quality of life, who accepted chemotherapy,radiotherapy, concurrent radiochemotherapy or who didn't accept therapy, after operation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study projects to follow up 180-200 early stage cervical cancer patients after operation and assess the women's quality of life by the scales: ECOG, Functional Assessment of Cancer Therapy, EuroQol-5 Dimensions, and Kupperman index.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Cervical Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≮ 18 years, cervical cancer verified by pathology，

* IIA stage, accepted the operation ( Piver III and pelvic lymph node dissection) as initial therapy， obtained the patient's agreement

Exclusion Criteria

* the patient had accepted chemotherapy or radiotherapy before operation

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yunong Gao

the head of department of gynecological oncology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gao Yunong

Role: STUDY_DIRECTOR

Peking University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gao Weijiao

Role: CONTACT

Phone: 86-10-88196102

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PUCRP201309

Identifier Type: -

Identifier Source: org_study_id